ProjektTWIGHLIGHT Study – Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Grunddaten
Akronym:
TWIGHLIGHT Study
Titel:
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
Laufzeit:
22.09.2015 bis 31.12.2018
Abstract / Kurz- beschreibung:
The primary objective of this study is to determine the impact of antiplatelet monotherapy with ticagrelor alone versus DAPT with ticagrelor plus aspirin for 12 months in reducing clinically relevant bleeding among high-risk patients undergoing PCI who have completed a 3-month course of aspirin plus ticagrelor.
The secondary objective of this study is to determine the impact of antiplatelet monotherapy with ticagrelor alone versus DAPT with ticagrelor plus aspirin for 12 months in reducing major ischemic adverse events among high-risk patients undergoing PCI who have completed a 3-month course of aspirin plus ticagrelor.
The secondary objective of this study is to determine the impact of antiplatelet monotherapy with ticagrelor alone versus DAPT with ticagrelor plus aspirin for 12 months in reducing major ischemic adverse events among high-risk patients undergoing PCI who have completed a 3-month course of aspirin plus ticagrelor.
Schlüsselwörter:
Herzkreislauferkrankungen
cardiovascular disease
Koronarstent
Thrombozytenaggregationshemmer
P2Y12-inhibitor
PTCA
Beteiligte Mitarbeiter/innen
Leiter/innen
Medizinische Universitätsklinik und Poliklinik (Department)
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Lokale Einrichtungen
Abteilung Innere Medizin III
Medizinische Universitätsklinik und Poliklinik (Department)
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät